| Recent bendamustine treatment before apheresis has a negative impact on outcomes in patients with large B-cell lymphoma receiving chimeric antigen receptor T-cell therapy G Iacoboni, ANA Martin Lopez, KA Jalowiec, M Kwon, K Rejeski, ... Blood 140 (Supplement 1), 1592-1594, 2022 | 30 | 2022 |
| Impact of cytomegalovirus replication in patients with aggressive B cell lymphoma treated with chimeric antigen receptor T cell therapy E Márquez-Algaba, G Iacoboni, B Pernas, J Esperalba, I Los Arcos, ... Transplantation and Cellular Therapy 28 (12), 851. e1-851. e8, 2022 | 13 | 2022 |
| Salvage treatment with novel agents is preferable to standard chemotherapy in patients with large B-cell lymphoma progressing after chimeric antigen receptor T-cell therapy G Iacoboni, J Iraola-Truchuelo, A Mussetti, P Fernández-Caldas, ... Blood 140 (Supplement 1), 378-380, 2022 | 10 | 2022 |
| Clinical and genomic characterisation of early-onset pancreatic cancer F Castet, C Fabregat-Franco, G Castillo, V Navarro, A Sierra, DA Acosta, ... European Journal of Cancer 194, 113338, 2023 | 6 | 2023 |
| Kinetics of cellular and humoral immunogenicity and effectiveness of SARS‐CoV‐2 booster vaccination in hematologic neoplasms M Jiménez, C Fernández‐Naval, V Navarro, S Novoa, M Martinez‐Gallo, ... American Journal of Hematology 98 (8), 1204-1213, 2023 | 6 | 2023 |
| Rethinking placebos: embracing synthetic control arms in clinical trials for rare tumors C Serrano, S Rothschild, G Villacampa, MC Heinrich, S George, JY Blay, ... Nature medicine 29 (11), 2689-2692, 2023 | 4 | 2023 |
| Clinical and psychological implications of secondary and incidental findings in cancer susceptibility genes after exome sequencing in patients with rare disorders E Carrasco, A López-Fernández, M Codina-Sola, I Valenzuela, ... Journal of Medical Genetics 60 (7), 685-691, 2023 | 3 | 2023 |
| P1151: BENDAMUSTINE-CONTAINING REGIMENS CAN BE SAFELY USED AS BRIDGING IN LARGE B-CELL LYMPHOMA PATIENTS RECEIVING CHIMERIC ANTIGEN RECEPTOR T-CELL THERAPY GII Garcia-Calvo, V Navarro, AAM Lopez, MB Oreiro, K Rejeski, ... HemaSphere 7 (S3), e48751b3, 2023 | 2 | 2023 |
| Haploidentical donor vs. Mismatch unrelated donor in reduced intensity conditioning transplant: A study from the spanish group of hematopoietic transplant and cell therapy … ML Fox, A Cabirta, A Pérez Martínez, A Esquirol, M Fonseca, ... Blood 140 (Supplement 1), 7631-7633, 2022 | 2 | 2022 |
| Impact of Prior Bendamustine Exposure on Bispecific Antibody Treatment Outcomes for Patients with B-Cell Lymphoma G Iacoboni, A Serna, VN Garces, AJ Ubieto, E Valencia, AL Garcia, ... Blood 142, 310, 2023 | 1 | 2023 |
| Resistance Mechanisms Impacting Bispecific Antibody (BsAbs) and Chimeric Antigen Receptor (CAR) T-Cell Therapy Outcomes in Large B Cell Lymphoma (LBCL) Patients J Iraola-Truchuelo, G Iacoboni, L Palomo, VN Garces, J Castellvi, A Mas, ... Blood 142, 1635, 2023 | 1 | 2023 |
| TP53 gene allelic state in myelodysplastic syndromes (MDS) with isolated 5q deletion J Montoro, L Palomo, C Haferlach, P Acha, O Chan, VN Garces, Y Kubota, ... Blood 142, 1001, 2023 | 1 | 2023 |
| PET‐based radiomics signature can predict durable responses to CAR T‐cell therapy in patients with large B‐cell lymphoma M Ligero, M Simó, C Carpio, G Iacoboni, M Balaguer‐Montero, V Navarro, ... EJHaem 4 (4), 1081-1088, 2023 | 1 | 2023 |
| Effect on outcomes of toxicity-related dose reduction in TKI monotherapy or TKI-IO combination therapy for advanced renal cell carcinoma. G Nuvola, DH Marmolejo Castañeda, V Mollica, M Santoni, ... Journal of Clinical Oncology 41 (16_suppl), 4528-4528, 2023 | 1 | 2023 |
| Comprehensive evaluation of surrogate endpoints to predict overall survival in trials with PD1/PD-L1 immune checkpoint inhibitors plus chemotherapy G Villacampa, PC Morgado, V Navarro, C Viaplana, R Dienstmann Cancer Treatment Reviews, 102542, 2023 | 1 | 2023 |
| Clinical impact of Sars-Cov-2 vaccination in COVID-19 outcomes in patients diagnosed with hematologic malignancies: real-world evidence of two years of pandemic M Jiménez, S Novoa Jáuregui, C Fernández-Naval, M Bosch Schips, ... Blood 140 (Supplement 1), 2628-2630, 2022 | 1 | 2022 |
| 711 Long-term survival women with advanced-stage high-grade serous carcinoma of the ovary, peritoneum, or fallopian tube: digging into their clinico-molecular features R Mazzeo, C Garcia-Duran, V Navarro-Garcés, L Fariñas-Madrid, ... International Journal of Gynecologic Cancer 34 (Suppl 1), 2024 | | 2024 |
| A whirl of radiomics-based biomarkers in cancer immunotherapy, why is large scale validation still lacking? B Gielen, P Cresta Morgado, O Prior, M Ligero, V Navarro Garces, ... Nature Portfolio, 2024 | | 2024 |
| Prevalence, Dynamics and Clinical Significance of Clonal Hematopoiesis of Indeterminate Potential (CHIP) in Newly Diagnosed Cancer Patients AP González, CP Jou, L Palomo, VN Garces, O Calvete, E Zamora, ... Blood 142, 5593, 2023 | | 2023 |
| Multi-Omics Exploration of Adaptive Mechanism to BTK Inhibition By Ibrutinib in CLL Identified TMBIM6/BI-1 As a Poor Prognosis Variable and Potential Therapeutic Target D Medina, L Palomo, V Navarro, O Castells, B Sánchez, PMM Torres, ... Blood 142, 3254, 2023 | | 2023 |
